Paxman AB ( (PXMBF) ) has released its Q3 earnings. Here is a breakdown of the information Paxman AB presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paxman AB is a leading company in the cryotherapy-based chemotherapy side effect management sector, known for its innovative scalp cooling technology aimed at preventing chemotherapy-induced alopecia. The company operates globally, with a strong presence in Europe, North America, and Asia, and is expanding its product line to include solutions for chemotherapy-induced peripheral neuropathy (CIPN).
In its latest earnings report for the third quarter of 2025, Paxman AB reported a significant increase in net sales, reaching 86.9 million SEK, a 34% rise compared to the same period last year. This growth was largely driven by the acquisition of Dignitana, a former competitor, which contributed 21.1 million SEK to the sales figures. Despite the increase in sales, the company’s net result showed a decline, with a net profit of 1.3 million SEK compared to 5.0 million SEK in the previous year, reflecting the costs associated with the merger and ongoing investments.
Key financial highlights include an EBITDA of 7.8 million SEK and a cash outflow of 19.9 million SEK, primarily due to debt repayments and continued investment activities. The company also reported a decrease in Average Daily Treatment Revenue (ADTR) excluding the acquisition, but an increase when including Dignitana’s contribution. The integration of Dignitana has been a strategic move, enhancing Paxman’s market position and expanding its installed base in the United States.
Looking forward, Paxman AB is optimistic about its growth prospects, with plans to fully integrate Dignitana by the end of 2025. The company is also focusing on expanding its recurring revenue streams and advancing its new CIPN device, which has shown promising results in clinical trials. With ongoing efforts to improve reimbursement pathways and legislative support for scalp cooling, Paxman is well-positioned to capitalize on these opportunities in the coming years.